Clinical Trial Update: Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating iparomlimab and tuvonralimab (QL1706) in HR-positive, HER2-negative advanced breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Wenjin Yin | Conditions: Advanced Breast Cancer | Phase 2 | Status: RECRUITING